Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...